Subhash C Chauhan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3998564/publications.pdf

Version: 2024-02-01

134 papers	8,860 citations	38720 50 h-index	45285 90 g-index
136 all docs	136 docs citations	136 times ranked	12995 citing authors

#	Article	IF	Citations
1	A topography of immunotherapies against gastrointestinal malignancies. Panminerva Medica, 2022, 64, .	0.2	3
2	The panoramic view of amyotrophic lateral sclerosis: A fatal intricate neurological disorder. Life Sciences, 2022, 288, 120156.	2.0	23
3	In Situ Nanoparticle Self-Assembly for Combination Delivery of Therapeutics to Non-Small Cell Lung Cancer. ACS Applied Bio Materials, 2022, 5, 1104-1119.	2.3	6
4	Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics. Pharmaceutics, 2022, 14, 611.	2.0	16
5	A global picture: therapeutic perspectives for COVID-19. Immunotherapy, 2022, 14, 351-371.	1.0	56
6	Tannic Acid Exhibits Antiangiogenesis Activity in Nonsmall-Cell Lung Cancer Cells. ACS Omega, 2022, 7, 23939-23949.	1.6	6
7	Emerging Roles and Potential Applications of Non-Coding RNAs in Cervical Cancer. Genes, 2022, 13, 1254.	1.0	6
8	COVID-19: fighting the invisible enemy with microRNAs. Expert Review of Anti-Infective Therapy, 2021, 19, 137-145.	2.0	63
9	CRISPR Systems for COVID-19 Diagnosis. ACS Sensors, 2021, 6, 1430-1445.	4.0	100
10	A bird eye view on cystic fibrosis: An underestimated multifaceted chronic disorder. Life Sciences, 2021, 268, 118959.	2.0	10
11	Clinical Implications of Exosomes: Targeted Drug Delivery for Cancer Treatment. International Journal of Molecular Sciences, 2021, 22, 5278.	1.8	16
12	Nanotechnology synergized immunoengineering for cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 72-101.	2.0	8
13	Milk exosomes: Nature's abundant nanoplatform for theranostic applications. Bioactive Materials, 2021, 6, 2479-2490.	8.6	72
14	Bioactive nanotherapeutic trends to combat triple negative breast cancer. Bioactive Materials, 2021, 6, 3269-3287.	8.6	31
15	Bay Leaf Extract-Based Near-Infrared Fluorescent Probe for Tissue and Cellular Imaging. Journal of Imaging, 2021, 7, 256.	1.7	0
16	Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. Biomedicines, 2021, 9, 1814.	1.4	1
17	Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Cells, 2020, 9, 103.	1.8	20
18	Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. British Journal of Cancer, 2020, 122, 121-131.	2.9	12

#	Article	IF	Citations
19	VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway. Cancer Letters, 2020, 470, 64-74.	3.2	10
20	Withania somnifera as a potential future drug molecule for COVID-19. Future Drug Discovery, 2020, 2, FDD50.	0.8	21
21	Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2. Bioconjugate Chemistry, 2020, 31, 2021-2045.	1.8	58
22	Topological and system-level protein interaction network (PIN) analyses to deduce molecular mechanism of curcumin. Scientific Reports, 2020, 10, 12045.	1.6	16
23	â€œTomorrow Never Diesâ€: Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. Diseases (Basel, Switzerland), 2020, 8, 30.	1.0	19
24	Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. European Journal of Pharmacology, 2020, 888, 173486.	1.7	30
25	miR-205: A Potential Biomedicine for Cancer Therapy. Cells, 2020, 9, 1957.	1.8	31
26	Smoking and COVID-19: Adding Fuel to the Flame. International Journal of Molecular Sciences, 2020, 21, 6581.	1.8	76
27	Role of Nutraceuticals in COVID-19 Mediated Liver Dysfunction. Molecules, 2020, 25, 5905.	1.7	11
28	Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188381.	3.3	60
29	Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells. ACS Omega, 2020, 5, 1147-1156.	1.6	4
30	Biophysical changes caused by altered MUC13 expression in pancreatic cancer cells. Micron, 2020, 130, 102822.	1.1	6
31	Tannic acid inhibits lipid metabolism and induce ROS in prostate cancer cells. Scientific Reports, 2020, 10, 980.	1.6	40
32	Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Efficacy. ACS Omega, 2020, 5, 8982-8991.	1.6	11
33	Neutralization of SARS-CoV-2 Spike Protein via Natural Compounds: A Multilayered High Throughput Virtual Screening Approach. Current Pharmaceutical Design, 2020, 26, 5300-5309.	0.9	3
34	Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 351.	1.8	45
35	APE1 Promotes Pancreatic Cancer Proliferation through GFRÎ±1/Src/ERK Axis-Cascade Signaling in Response to GDNF. International Journal of Molecular Sciences, 2020, 21, 3586.	1.8	20
36	A Novel Technique for the Detection of LncRNAs on Tissue Sections. Springer Protocols, 2020, , 237-243.	0.1	0

#	Article	IF	Citations
37	Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions. Hpb, 2019, 21, 87-95.	0.1	9
38	A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth. Scientific Reports, 2019, 9, 10917.	1.6	8
39	Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics, 2019, 11, 574.	2.0	58
40	Ormeloxifene nanotherapy for cervical cancer treatment . International Journal of Nanomedicine, 2019, Volume 14, 7107-7121.	3.3	12
41	Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence. ACS Applied Materials & Interfaces, 2019, 11, 38537-38554.	4.0	29
42	Therapeutic efficacy of a novel Î²III/Î²IV-tubulin inhibitor (VERU-111) in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 29.	3.5	25
43	Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102027.	1.7	18
44	Cucurbitacin D Reprograms Glucose Metabolic Network in Prostate Cancer. Cancers, 2019, 11, 364.	1.7	26
45	Dietary fatty acids fine-tune Piezo1 mechanical response. Nature Communications, 2019, 10, 1200.	5.8	169
46	Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials, 2019, 208, 83-97.	5.7	100
47	Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting. Biochemistry and Biophysics Reports, 2019, 17, 197-207.	0.7	35
48	Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. Journal of Colloid and Interface Science, 2019, 535, 133-148.	5.0	109
49	Targeting Îºappa B kinases for cancer therapy. Seminars in Cancer Biology, 2019, 56, 12-24.	4.3	39
50	Optical detection of the structural properties of tumor tissue generated by xenografting of drug-sensitive and drug-resistant cancer cells using partial wave spectroscopy (PWS). Biomedical Optics Express, 2019, 10, 6422.	1.5	7
51	Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1. British Journal of Cancer, 2018, 118, 587-599.	2.9	14
52	MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. Oncogenesis, 2018, 7, 19.	2.1	29
53	Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. Hpb, 2018, 20, 563-572.	0.1	19
54	Targeted and theranostic applications for nanotechnologies in medicine. , 2018, , 399-511.		7

#	Article	IF	Citations
55	Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer. Acta Pharmaceutica Sinica B, 2018, 8, 602-614.	5.7	50
56	Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes. Drug Discovery Today, 2018, 23, 1635-1643.	3.2	84
57	Quantification of photonic localization properties of targeted nuclear mass density variations: Application in cancerâ€stage detection. Journal of Biophotonics, 2018, 11, e201700257.	1.1	10
58	Z Probe, An Efficient Tool for Characterizing Long Non-Coding RNA in FFPE Tissues. Non-coding RNA, 2018, 4, 20.	1.3	8
59	miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. Cancers, 2018, 10, 289.	1.7	41
60	Tannic Acid-Lung Fluid Assemblies Promote Interaction and Delivery of Drugs to Lung Cancer Cells. Pharmaceutics, 2018, 10, 111.	2.0	17
61	Tannic Acid Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Prostate Cancer. Cancers, 2018, 10, 68.	1.7	44
62	Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals, 2018, 11, 32.	1.7	161
63	Optical study of chemotherapy efficiency in cancer treatment via intracellular structural disorder analysis using partial wave spectroscopy. Journal of Biophotonics, 2018, 11, e201800056.	1.1	9
64	Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic Î²-catenin Signaling and EMT Progression. Molecular Cancer Therapeutics, 2017, 16, 2267-2280.	1.9	43
65	Magnetic nanoformulations for prostate cancer. Drug Discovery Today, 2017, 22, 1233-1241.	3.2	19
66	Probing mucin interaction behavior of magnetic nanoparticles. Journal of Colloid and Interface Science, 2017, 488, 258-268.	5.0	30
67	miRNA nanotherapeutics for cancer. Drug Discovery Today, 2017, 22, 424-432.	3.2	240
68	Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. Journal of Gastrointestinal Surgery, 2017, 21, 94-105.	0.9	42
69	Disparity in rates of HPV infection and cervical cancer in underserved US populations. Frontiers in Bioscience - Scholar, 2017, 9, 254-269.	0.8	12
70	Abstract 1206: miR-205 replenishment in prostate cancer cells: A novel nanoparticle approach. , 2017, , .		1
71	miR-145: Revival of a Dragon in Pancreatic Cancer. Journal of Nature and Science, 2017, 3, .	1.1	2
72	PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids and Surfaces B: Biointerfaces, 2016, 144, 8-20.	2.5	106

#	Article	IF	Citations
73	Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Scientific Reports, 2016, 6, 36594.	1.6	63
74	Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy. Cell Stress and Chaperones, 2016, 21, 313-326.	1.2	12
75	Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. Tumor Biology, 2016, 37, 685-698.	0.8	55
76	Polyester Particles for Curcumin Delivery. , 2016, , 651-673.		0
77	Slit/Robo pathway: a promising therapeutic target for cancer. Drug Discovery Today, 2015, 20, 156-164.	3.2	83
78	Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. Biomaterials, 2015, 46, 1-12.	5.7	145
79	Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials, 2015, 53, 731-743.	5.7	40
80	Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer. Cancer Research, 2015, 75, 2292-2304.	0.4	67
81	Therapeutic Applications of Curcumin Nanoformulations. AAPS Journal, 2015, 17, 1341-1356.	2.2	262
82	Ormeloxifene efficiently inhibits ovarian cancer growth. Cancer Letters, 2015, 356, 606-612.	3.2	22
83	The Roles of Cellular Nanomechanics in Cancer. Medicinal Research Reviews, 2015, 35, 198-223.	5.0	34
84	Revisiting stroma in pancreatic cancer. Oncoscience, 2015, 2, 819-820.	0.9	2
85	Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1. Current Drug Metabolism, 2015, 16, 486-503.	0.7	69
86	Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials, 2014, 35, 8635-8648.	5.7	232
87	Functions and regulation of MUC13 mucin in colon cancer cells. Journal of Gastroenterology, 2014, 49, 1378-1391.	2.3	45
88	Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resistance Updates, 2014, 17, 13-23.	6.5	80
89	Protein Kinase D1 attenuates tumorigenesis in colon cancer by modulating Î²-catenin/T cell factor activity. Oncotarget, 2014, 5, 6867-6884.	0.8	20
90	MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget, 2014, 5, 7599-7609.	0.8	98

#	Article	IF	Citations
91	Novel Curcumin-Loaded Magnetic Nanoparticles for Pancreatic Cancer Treatment. Molecular Cancer Therapeutics, 2013, 12, 1471-1480.	1.9	112
92	Targeting microRNAs in Pancreatic Cancer: Microplayers in the Big Game. Cancer Research, 2013, 73, 6541-6547.	0.4	75
93	MicroRNA Profiling in Prostate Cancer - The Diagnostic Potential of Urinary miR-205 and miR-214. PLoS ONE, 2013, 8, e76994.	1.1	149
94	Anti-Cancer Potential of a Novel SERM Ormeloxifene. Current Medicinal Chemistry, 2013, 20, 4177-4184.	1.2	32
95	Curcumin Nanomedicine: A Road to Cancer Therapeutics. Current Pharmaceutical Design, 2013, 19, 1994-2010.	0.9	100
96	Plasma Proteins Interaction with Curcumin Nanoparticles: Implications in Cancer Therapeutics. Current Drug Metabolism, 2013, 14, 504-515.	0.7	34
97	Curcumin Attenuates Î²-catenin Signaling in Prostate Cancer Cells through Activation of Protein Kinase D1. PLoS ONE, 2012, 7, e35368.	1.1	81
98	Increased Expression and Aberrant Localization of Mucin 13 in Metastatic Colon Cancer. Journal of Histochemistry and Cytochemistry, 2012, 60, 822-831.	1.3	41
99	MUC13 Mucin Augments Pancreatic Tumorigenesis. Molecular Cancer Therapeutics, 2012, 11, 24-33.	1.9	81
100	Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. International Journal of Nanomedicine, 2012, 7, 1761.	3.3	125
101	Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discovery Today, 2012, 17, 71-80.	3.2	569
102	Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. Genes and Nutrition, 2012, 7, 83-89.	1.2	19
103	Risk factors for HPV infection among American Indian and white women in the Northern Plains. Gynecologic Oncology, 2011, 121, 532-536.	0.6	31
104	Design and engineering of nanogels for cancer treatment. Drug Discovery Today, 2011, 16, 457-463.	3.2	165
105	HPV infection among rural American Indian women and urban white women in South Dakota: an HPV prevalence study. BMC Infectious Diseases, 2011, 11, 252.	1.3	17
106	Curcumin suppresses human papillomavirus oncoproteins, restores p53, rb, and ptpn13 proteins and inhibits benzo[a]pyreneâ€induced upregulation of HPV E7. Molecular Carcinogenesis, 2011, 50, 47-57.	1.3	88
107	Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials, 2011, 32, 1890-1905.	5.7	418
108	Mucin 13: Structure, Function, and Potential Roles in Cancer Pathogenesis. Molecular Cancer Research, 2011, 9, 531-537.	1.5	68

#	Article	IF	Citations
109	Emerging Roles of Protein Kinase D1 in Cancer. Molecular Cancer Research, 2011, 9, 985-996.	1.5	69
110	Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. International Journal of Nanomedicine, 2011, 6, 2779.	3.3	52
111	Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Research, 2011, 31, 897-906.	0.5	65
112	Poly(Î²â€cyclodextrin)/Curcumin Selfâ€Assembly: A Novel Approach to Improve Curcumin Delivery and its Therapeutic Efficacy in Prostate Cancer Cells. Macromolecular Bioscience, 2010, 10, 1141-1151.	2.1	117
113	Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. Journal of Colloid and Interface Science, 2010, 351, 19-29.	5.0	484
114	Î²-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids and Surfaces B: Biointerfaces, 2010, 79, 113-125.	2.5	438
115	Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. Journal of Ovarian Research, 2010, 3, 11.	1.3	170
116	Scope of nanotechnology in ovarian cancer therapeutics. Journal of Ovarian Research, 2010, 3, 19.	1.3	34
117	Expression and Functions of Transmembrane Mucin MUC13 in Ovarian Cancer. Cancer Research, 2009, 69, 765-774.	0.4	102
118	Mucins in ovarian cancer diagnosis and therapy. Journal of Ovarian Research, 2009, 2, 21.	1.3	54
119	Epidemiology of Human Papilloma Virus (HPV) in Cervical Mucosa. Methods in Molecular Biology, 2009, 471, 439-456.	0.4	22
120	Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells. Biochemical and Biophysical Research Communications, 2008, 373, 618-623.	1.0	33
121	MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells. Cancer Research, 2008, 68, 2065-2070.	0.4	148
122	Bryostatin 1 modulates Î²-catenin subcellular localization and transcription activity through protein kinase D1 activation. Molecular Cancer Therapeutics, 2008, 7, 2703-2712.	1.9	35
123	Combined Staining of TAG-72, MUC1, and CA125 Improves Labeling Sensitivity in Ovarian Cancer. Journal of Histochemistry and Cytochemistry, 2007, 55, 867-875.	1.3	31
124	Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Letters, 2007, 251, 247-257.	3.2	36
125	There is a high prevalence of human papillomavirus infection in American Indian women of the Northern Plains. Gynecologic Oncology, 2007, 107, 236-241.	0.6	39
126	Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate, 2006, 66, 421-429.	1.2	90

#	Article	IF	Citations
127	Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Modern Pathology, 2006, 19, 1386-1394.	2.9	133
128	Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 264-273.	3.3	32
129	Penetratin Improves Tumor Retention of Single-Chain Antibodies: A Novel Step toward Optimization of Radioimmunotherapy of Solid Tumors. Cancer Research, 2005, 65, 7840-7846.	0.4	83
130	Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49. Biochemical and Biophysical Research Communications, 2005, 329, 168-176.	1.0	11
131	The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nuclear Medicine and Biology, 2005, 32, 157-164.	0.3	36
132	Inhibition of MUC4 Expression Suppresses Pancreatic Tumor Cell Growth and Metastasis. Cancer Research, 2004, 64, 622-630.	0.4	224
133	Human Sperm-Specific Peptide Vaccine That Causes Long-Term Reversible Contraception1. Biology of Reproduction, 2002, 67, 674-680.	1.2	57
134	Pharmacokinetics and biodistribution of genetically engineered antibodies. Current Opinion in Biotechnology, 2002, 13, 603-608.	3.3	189